A phase 1 trial utilizing TMI with fludarabine-melphalan in patients with hematologic malignancies undergoing second allo-SCT. uri icon

authors

  • Tran, Misha C
  • Kline, Justin
  • Riedell, Peter A
  • Andrew Artz, MD, MS
  • Weichselbaum, Ralph
  • Bishop, Michael R
  • Aydogan, Bulent
  • Liu, Hongtao
  • Hasan, Yasmin
  • Wang, Amy
  • Yenice, Kamil
  • Partouche, Julien
  • Stock, Wendy
  • Larson, Richard A
  • Kosuri, Satyajit
  • LaBelle, James L

publication date

  • January 1, 2022